Alkem Laboratories Limited

Equities

ALKEM

INE540L01014

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:51 2024-05-31 am EDT 5-day change 1st Jan Change
4,810 INR -2.76% Intraday chart for Alkem Laboratories Limited -11.76% -7.54%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Alkem Laboratories' Consolidated Profit Soars in Fiscal Q4; Shares Slump 6% MT
Jefferies Adjusts Alkem Laboratories’ Price Target to INR4,200 From INR4,470, Keeps at Underperform MT
Transcript : Alkem Laboratories Limited, Q4 2024 Earnings Call, May 29, 2024
Alkem Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2024, Payable on and from 4 September, 2024 CI
Alkem Laboratories Limited Receives an Order Passed by Additional Commissioner, Office of Additional Commissioner, Central GST SUB. - Commissionerate, Mohali: Chandigarh CI
Alkem Laboratories Limited Receives Order from Assistant Commissioner, GST & Central Excise, Cuttack-II Division, Cuttack and Superintendent, Central GST & Central Excise, Cuttack-II Division, Cuttack CI
Alkem Laboratories Limited Receives an Order from Assistant Commissioner, Ghatak 55, Range-14, Division­ 6, Gujarat CI
Alkem Laboratories Limited Receives A Demand Order Levying A Penalty of INR 35,099 State Tax Officer, Ghatak CI
Alkem Laboratories Forms Subsidiary for Medical Devices Business MT
Alkem Laboratories Limited Announces Incorporation of Subsidiary Alkem Medtech Private Limited CI
Alkem Laboratories Gets 10 Observations from US FDA After Baddi, India Unit Inspection MT
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy MT
Jefferies Adjusts Alkem Laboratories’ Price Target to INR4,470 From INR3,960, Keeps at Underperform MT
Transcript : Alkem Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024
Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024 CI
Alkem Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Indian Equities Close Higher on Friday, Lifted by IT Stocks MT
Alkem Laboratories Names Successor to Outgoing CFO MT
Alkem Laboratories Limited Announces CFO Changes CI
Heritage Global, Investors Acquire Pharmaceutical Plant from Alkem Laboratories MT
Federal Machinery & Equipment Co., Heritage Global Partners, Inc., New Mill Capital LLC, Keith Machinery Corp acquired Pharmaceutical Site in Fenton Missouri from Alkem Laboratories Limited. CI
Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023 CI
Alkem Laboratories Limited Submits Clinical Trial Application to Central Drugs Standard Control Organization in India CI
Alkem Laboratories Limited Submits Clinical Trial Application for First Patient Study with Bsg005 in Invasive Fungal Infections in India as A Rescue Therapy CI
Chart Alkem Laboratories Limited
More charts
Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
4,810 INR
Average target price
5,152 INR
Spread / Average Target
+7.10%
Consensus
  1. Stock Market
  2. Equities
  3. ALKEM Stock
  4. News Alkem Laboratories Limited
  5. Alkem Laboratories' Consolidated Profit Jumps in Fiscal Q1; Shares Drop 7%